Academic Component Sample Clauses

Academic Component. I agree to complete all required readings, evaluations, and/or other assignments required by the faculty supervisor.
Sample 1Sample 2Sample 3See All (8)
AutoNDA by SimpleDocs
Academic Component. I agree to complete all required readings, evaluations, and/or other assignments required by the site and faculty supervisors. Opportunities for Reflection: I will reflect on the observations, experiences, ethical considerations, and other issues that arise during my externship. As directed by my faculty supervisor, I will submit reflection papers or journals analyzing my experiences. In so doing, I will be mindful of my confidentiality obligations. Self-Evaluation: I will strive to self-assess on each assignment I complete. In so doing, I will consider what I did effectively and areas for improvement. Where possible and appropriate, I will discuss my self-assessment with my faculty and site supervisors. I will be open to feedback from my supervisors and will consider how it can be applied specifically and globally to my future work. My externship Start Date is: . The End Date is: . I am enrolled in (#) units for this externship. I understand that to receive credit I must on average (#) hours per week for (#) of weeks, for a total of hours during the session. (Please see the Externship Syllabus for hours-per-unit information.) During this session, I have the following classes and commitments in addition to my externship. In addition to class, examples of commitments include work, office hours, public service, and any other regularly-scheduled events/meetings. Name of Class/Commitment Day/Time/# Hours per week _ Please also indicate whether you will be receiving any compensation for the externship (e.g., hourly wage, transportation/parking cost from the placement or a grant from a third party). Yes No . If “yes,” please explain:
Sample 1
Academic Component. Your faculty sponsor will evaluate the success of the internship from an academic perspective. Please outline the academic component of this experience. Example: “I will be working with Professor (full-time faculty member) to complete a weekly journal, read three journal articles on advertising in society, and a final research paper of 8-10 pages in length.” ] The academic component can take several forms ranging from a number of short papers to a major research report to an artistic portfolio or videotape. There is certainly room for creativity on your part. Advertising interns, for example, often do mock xx xxxxxxxxx; human services interns can present case studies; and brokerage interns might put together several mock portfolios, researching and evaluating the stocks chosen. Although many faculty assign a journal as one method of evaluation, a journal alone is not sufficient. There must be one or more additional projects/assignments that can be evaluated. ] Your final project should be equivalent to an 8-10 page paper for a one-unit internship and an 18-20 page paper for a two-unit internship. Xxxxx University Career Services 000 Xxxxxxxx Xx. (Alumni/Career Services house) Telephone: (000) 000-0000 Worcester, MA 00000-0000 Fax: (000) 000-0000 Website: xxx.xxxxxx.xxx/xxxxxxx/xxxxxx Email: xxxxxxx@xxxxxx.xxx Internship Sponsor Agreement Form Student Intern Name: Sponsoring Organization Name: Street Address: City: State: Zip: Phone: ( ) Fax: ( ) Website: Supervisor Name: Title: Phone: ( ) Department: Fax: ( ) Email: Does your company have a safety program, or documented policies and procedures relating to safety within your company? □ Yes □ No Do you have a safety-training program? □ Yes □ No Is your company/organization insured? □ Yes □ No If possible, please forward to Xxxxx University Career Services a Certificate of Insurance covering the period of the student’s work assignment. Signature: Date: Xxxxx University Career Services Internship Hours Tracking Sheet Student Name: _ _ Internship Site: __ _ Email: __ _ Week Sunday Monday Tuesday Wednesday Thursday Friday Saturday Totals 3 4 5 6 7 8 9 10 11 12 13 14 Total Number of Hours: _ Site Supervisor’s signature: _ _ Date: _
Sample 1
Academic Component. I agree to complete all required readings, evaluations, and/or other assignments requested by the Faculty Supervisor and TLC Externship Program.
Sample 1

Related to Academic Component

  • Combination Product The term “

  • Combination Products If a LICENSED PRODUCT , DISCOVERY PRODUCT and/or THERAPEUTIC PROUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Separation of Components The SOFTWARE PRODUCT is licensed as a single product. Its component parts may not be separated for use on more than one computer.

  • SHOP DRAWINGS, PRODUCT DATA AND SAMPLES 4.12.1 Shop Drawings are drawings, diagrams, schedules and other, data specially prepared for the Work by the Contractor or any Subcontractor, manufacturer, supplier or distributor to illustrate some portion of the Work.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Time is Money Join Law Insider Premium to draft better contracts faster.